180 related articles for article (PubMed ID: 34148553)
1. ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis.
Zhang Y; Cao S; Zhuang C; Chen J; Chen X; Sun H; Lin S; Lin B
J Ovarian Res; 2021 Jun; 14(1):80. PubMed ID: 34148553
[TBL] [Abstract][Full Text] [Related]
2. ERCC1 expression and platinum chemosensitivity in patients with ovarian cancer: A meta-analysis.
Zhang C; Gao S; Hou J
Int J Biol Markers; 2020 Dec; 35(4):12-19. PubMed ID: 33126828
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of excision repair cross complementary gene 1 (ERCC1) expression and platinum chemosensitivity in patients with ovarian cancer.
Wu J; Li R; Chen X; Chen C; Chen H; Ma B
Ann Palliat Med; 2020 Sep; 9(5):3428-3435. PubMed ID: 33065793
[TBL] [Abstract][Full Text] [Related]
4. Effect of ERCC1 polymorphisms on the response to platinum-based chemotherapy: A systematic review and meta-analysis based on Asian population.
Wu X; Lu W; Jiang C; Zhang D; Zhang W; Cui Y; Zhuo Z; Mei H; Wang Y; Zhang M; Chen S
PLoS One; 2023; 18(5):e0284825. PubMed ID: 37141338
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy.
Li F; Xie X; Ren X; Zhang J
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1183-91. PubMed ID: 27100737
[TBL] [Abstract][Full Text] [Related]
6. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
7. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
[TBL] [Abstract][Full Text] [Related]
8. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis.
Tang N; Lyu D; Zhang Y; Liu H
BMC Womens Health; 2017 Jun; 17(1):43. PubMed ID: 28623887
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of excision repair cross-complementation group 1 (ERCC1) association with response to platinum- based chemotherapy in ovarian cancer.
Li FY; Ren XB; Xie XY; Zhang J
Asian Pac J Cancer Prev; 2013; 14(12):7203-6. PubMed ID: 24460276
[TBL] [Abstract][Full Text] [Related]
10. Association between ERCC1 Gene Polymorphism (rs11615) and Colorectal Cancer Susceptibility: A Meta-Analysis of Medical Image Fusion and Safety Applications.
Liu M; Qiu Z; Yang Q
Comput Math Methods Med; 2022; 2022():9988513. PubMed ID: 36277013
[TBL] [Abstract][Full Text] [Related]
11.
Li B; Shi X; Yuan Y; Peng M; Jin H; Qin D
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29752341
[TBL] [Abstract][Full Text] [Related]
12. The role of single nucleotide polymorphisms of the ERCC1 and MMS19 genes in predicting platinum-sensitivity, progression-free and overall survival in advanced epithelial ovarian cancer.
Moxley KM; Benbrook DM; Queimado L; Zuna RE; Thompson D; McCumber M; Premkumar P; Thavathiru E; Hines L; Moore KN
Gynecol Oncol; 2013 Aug; 130(2):377-82. PubMed ID: 23632208
[TBL] [Abstract][Full Text] [Related]
13. Association of Rs11615 (C>T) in the excision repair cross-complementing group 1 gene with ovarian but not gynecological cancer susceptibility: a meta-analysis.
Ma YJ; Feng SC; Hu SL; Zhuang SH; Fu GH
Asian Pac J Cancer Prev; 2014; 15(15):6071-4. PubMed ID: 25124575
[TBL] [Abstract][Full Text] [Related]
14. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
15. Meta-Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non-Small-Cell Lung Cancer.
Li G; Cheng D
Evid Based Complement Alternat Med; 2020; 2020():7376568. PubMed ID: 32419821
[TBL] [Abstract][Full Text] [Related]
16. ERCC1 expression levels predict the outcome of platinum-based chemotherapies in advanced bladder cancer: a meta-analysis.
Li S; Wu J; Chen Y; Tang W; Peng Q; Deng Y; Xie L; Wang J; Huang S; Li R; Qin X; Zhao J
Anticancer Drugs; 2014 Jan; 25(1):106-14. PubMed ID: 24025563
[TBL] [Abstract][Full Text] [Related]
17. [The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].
Zhao D; Zhang W; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):196-200. PubMed ID: 22780973
[TBL] [Abstract][Full Text] [Related]
18. The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis.
Wei KK; Jiang L; Wei YY; Wang YF; Qian XK; Dai Q; Guan QL
Tumour Biol; 2014 Sep; 35(9):8721-31. PubMed ID: 24870596
[TBL] [Abstract][Full Text] [Related]
19. Association between polymorphisms of ERCC1 and survival in epithelial ovarian cancer patients with chemotherapy.
Yan L; Shu-Ying Y; Shan K; Yip BH; Rong-Miao Z; Na W; Hai-Yan S
Pharmacogenomics; 2012 Mar; 13(4):419-27. PubMed ID: 22329723
[TBL] [Abstract][Full Text] [Related]
20. The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinum-based chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis.
Yang Y; Xian L
Tumour Biol; 2014 Apr; 35(4):2905-21. PubMed ID: 24338713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
